{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:20:22Z","timestamp":1788402022460,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Background<\/jats:title>\n Premature myocardial infarction (PMI) is increasingly recognized as a metabolic disease, driven by a cluster of dysregulations including insulin resistance and central obesity. While homocysteine (Hcy)\u2014an intermediate of one-carbon metabolism\u2014is implicated in these atherothrombotic processes, its synergistic effect with coexisting cardiometabolic risk factors for the long-term prognosis of PMI patients remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a prospective cohort study of 1,220 consecutive PMI patients who underwent percutaneous coronary intervention (PCI) (men \u226445 years, women \u226455 years) at Tianjin Chest Hospital from January 2017 to December 2024. Plasma Hcy was measured at baseline and classified as high (\u226515 \u00b5mol\/L) or normal (&lt;15 \u00b5mol\/L). The primary endpoint was major adverse cardiovascular events (MACE), including cardiac death, rehospitalization for severe heart failure, non-fatal myocardial infarction, ischemic stroke, readmission for unstable angina, and target lesion revascularization. Multivariable Cox models and joint effect analyses were used to assess independent and synergistic associations.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Over a median follow-up of 582 days, 136 patients (11.1%) experienced MACE. After multivariable adjustment, high Hcy remained independently associated with MACE (aHR=2.72; 95% CI 1.87-3.95, P&lt;0.001). This risk was higher when cardiometabolic factors coexisted, increasing from a 3.1-to 4.1-fold higher risk when combined with high D-Dimer, high-normal blood pressure, Lp(a), or hs-CRP (aHRs 3.13-4.12), to a 6.5-fold higher risk with coexisting obesity (aHR=6.54; 95% CI 3.01-14.20, P&lt;0.001) compared to patients with normal Hcy and normal BMI. In the exploratory three-way analyses, the combination of high Hcy, obesity, and elevated D-Dimer (D-Dimer&gt;0.5mg\/L) conferred a nearly 10-fold higher risk (aHR=9.91; 95% CI 3.68\u201326.66, P&lt;0.001), while the triad of high Hcy, obesity, and high hs-CRP (hs-CRP &gt;2 mg\/L) was associated with a 17.5-fold higher risk (aHR=17.51; 95% CI 2.28-134.52, P=0.006).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Elevated plasma Hcy is an independent predictor of MACE in PMI patients and may be used to identify subgroups at particularly high risk. This effect is more pronounced in individuals who are obese or have other adverse metabolic characteristics.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1821132","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:41:12Z","timestamp":1778215272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Elevated homocysteine associated with higher cardiovascular risk in young patients with myocardial infarction: the role of metabolic phenotypes"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing-yu","family":"Liu","sequence":"first","affiliation":[{"name":"Clinical School of Thoracic, Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Cardiology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-hang","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical School of Thoracic, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-ping","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Cui","sequence":"additional","affiliation":[{"name":"School of Public Health, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"Clinical School of Thoracic, Tianjin Medical University","place":["Tianjin, China"]},{"name":"Chest Hospital, Tianjin University","place":["Tianjin, China"]},{"name":"Cardiovascular Institute, Tianjin Chest Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.11.003","article-title":"Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants","volume":"9","author":"Wang","year":"2022","journal-title":"Genes Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3502","article-title":"Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors","volume":"38","author":"Silveira Rossi","year":"2021","journal-title":"Diabetes\/Metabolism Res Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20174963","article-title":"Prevalence of metabolic syndrome in patients with premature coronary artery disease proven by coronary angiogram","volume":"5","author":"Sundaramoorthy","year":"2017","journal-title":"Int J Res Med Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis \u2014 from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1179807","article-title":"Homocysteine-a retrospective and prospective appraisal","volume":"10","author":"McCaddon","year":"2023","journal-title":"Front Nutr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13030254","article-title":"Diabetic retinopathy and regulation of mitochondrial glutathione\u2013glutathione peroxidase axis in hyperhomocysteinemia","volume":"13","author":"Malaviya","year":"2024","journal-title":"Antioxidants"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2457527","article-title":"Role of hyperhomocysteinemia in atherosclerosis: from bench to bedside","volume":"57","author":"Tian","year":"2025","journal-title":"Ann Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125471","article-title":"Homocysteinylation of fibrinogen: A post-translational link to thrombosis","volume":"26","author":"Giurranna","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-01869-y","article-title":"Associations between hyperhomocysteinemia and the presence and severity of acute coronary syndrome in young adults\u2009\u2264\u200935 years of age","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000025677","article-title":"Clinical implication of homocysteine in premature acute coronary syndrome female patients","volume":"100","author":"Zhao","year":"2021","journal-title":"Medicine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.70080","article-title":"Intervention at circulating homocysteine levels >10 \u00b5mol\/L for primary prevention of cardiovascular diseases: A systematic review and dose\u2013response meta\u2010analysis","volume":"18","author":"Huang","year":"2025","journal-title":"J Evidence-Based Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006612.pub5","article-title":"Homocysteine-lowering interventions for preventing cardiovascular events","volume":"2021","author":"Mart\u00ed-Carvajal","year":"2017","journal-title":"Cochrane Database Sys Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319894679","article-title":"No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study","volume":"28","author":"Miao","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0774-8","article-title":"Homocysteine is a bystander for ST-segment elevation myocardial infarction: a case-control study","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf281","article-title":"Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events","volume":"46","author":"Markus","year":"2025","journal-title":"Eur Heart J"},{"key":"B16","article-title":"Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)","year":"2024","journal-title":"National Health Commission of the People\u2019s Republic of China"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes. (Standards of Care in Diabetes \u2014 2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/00033197211019805","article-title":"Prognostic value of baseline d-dimer level in patients with coronary artery disease: A meta-analysis","volume":"73","author":"Zhang","year":"2021","journal-title":"Angiology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.047","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement","volume":"87","author":"Mensah","year":"2025","journal-title":"Jacc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.16439\/j.issn.1673-7245.2024.07.002","article-title":"Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 Revised Edition)","volume":"32","year":"2024","journal-title":"Chin J Hypertens"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-024-00460-y","article-title":"Association between homocysteine and coronary artery disease\u2014trend over time and across the regions: a systematic review and meta-analysis","volume":"76","author":"Unadkat","year":"2024","journal-title":"Egyp Heart J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.advnut.2025.100434","article-title":"Homocysteine and multiple health outcomes: An outcome-wide umbrella review of meta-analyses and Mendelian randomization studies","volume":"16","author":"Zhou","year":"2025","journal-title":"Adv Nutr"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01942-0","article-title":"Comprehensive transcriptomics and metabolomics analyses reveal that hyperhomocysteinemia is a high risk factor for coronary artery disease in a chinese obese population aged 40\u201365: a prospective cross-sectional study","volume":"22","author":"Zhang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020746","article-title":"Homocysteine metabolites, endothelial dysfunction, and cardiovascular disease","volume":"26","author":"Jakubowski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22074","article-title":"Inhibition of adiponectin production by homocysteine: A potential mechanism for alcoholic liver disease","volume":"47","author":"Song","year":"2008","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezad406","article-title":"Homocysteine impairs the anticontractile\/vasorelaxing activity of perivascular adipose tissue surrounding human internal mammary artery","volume":"64","author":"Wei","year":"2023","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109821","article-title":"Homocysteine inhibits pro-insulin receptor cleavage and causes insulin resistance via protein cysteine-homocysteinylation","volume":"37","author":"Zhang","year":"2021","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.431627","article-title":"Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue","volume":"288","author":"Li","year":"2013","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101742","article-title":"Homocysteine promotes hepatic steatosis by activating the adipocyte lipolysis in a HIF1\u03b1-ERO1\u03b1-dependent oxidative stress manner","volume":"37","author":"Yan","year":"2020","journal-title":"Redox Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0385","article-title":"Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications","volume":"63","author":"Pinnick","year":"2014","journal-title":"Diabetes"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51698","article-title":"The influence of anthropometrics on cardiac mechanics in healthy women with opposite obesity phenotypes (android vs gynoid)","volume":"16","author":"Sonaglioni","year":"2024","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275956","article-title":"Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure\/function in coronary artery disease","volume":"17","author":"Nusca","year":"2022","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuae191","article-title":"Effect of nutritional supplements for reducing homocysteine levels in healthy adults: A systematic review and network meta-analysis of randomized trials","volume":"83","author":"Liu","year":"2025","journal-title":"Nutr Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.550753","article-title":"Association between folate and health outcomes: An umbrella review of meta-analyses","volume":"8","author":"Bo","year":"2020","journal-title":"Front Public Health"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2021.1902938","article-title":"Effects of betaine supplementation on cardiovascular markers: A systematic review and meta-analysis","volume":"62","author":"Ashtary-Larky","year":"2021","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.16689\/j.cnki.cn11-9349\/r.2020.03.007","article-title":"Expert Consensus on the Diagnosis and Treatment of Hyperhomocysteinemia","volume":"7","year":"2020","journal-title":"Electron J Metab Nutr Cancer"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1821132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:41:27Z","timestamp":1778215287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1821132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":37,"alternative-id":["10.3389\/fendo.2026.1821132"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1821132","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1821132"}}